CN101641332B - 用于治疗癌症的胺化的羟基喹啉类衍生物 - Google Patents

用于治疗癌症的胺化的羟基喹啉类衍生物 Download PDF

Info

Publication number
CN101641332B
CN101641332B CN200880007473.7A CN200880007473A CN101641332B CN 101641332 B CN101641332 B CN 101641332B CN 200880007473 A CN200880007473 A CN 200880007473A CN 101641332 B CN101641332 B CN 101641332B
Authority
CN
China
Prior art keywords
group
hydroxyquinoline
methylene
groups
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880007473.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN101641332A (zh
Inventor
让-路易斯·克劳斯
奥利维耶·布兰
弗雷德里克·卡姆帕韦雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOPHARMED A RESPONSABILITE Ltee Ste
Original Assignee
BIOPHARMED A RESPONSABILITE Ltee Ste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIOPHARMED A RESPONSABILITE Ltee Ste filed Critical BIOPHARMED A RESPONSABILITE Ltee Ste
Publication of CN101641332A publication Critical patent/CN101641332A/zh
Application granted granted Critical
Publication of CN101641332B publication Critical patent/CN101641332B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN200880007473.7A 2007-03-23 2008-03-25 用于治疗癌症的胺化的羟基喹啉类衍生物 Expired - Fee Related CN101641332B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR07/02154 2007-03-23
FR0702154A FR2913976B1 (fr) 2007-03-23 2007-03-23 Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.
PCT/FR2008/000399 WO2008135671A2 (fr) 2007-03-23 2008-03-25 Dérivés de la classe des hydroxyquinoléines aminées pour le traitement de cancers.

Publications (2)

Publication Number Publication Date
CN101641332A CN101641332A (zh) 2010-02-03
CN101641332B true CN101641332B (zh) 2014-03-12

Family

ID=38686734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880007473.7A Expired - Fee Related CN101641332B (zh) 2007-03-23 2008-03-25 用于治疗癌症的胺化的羟基喹啉类衍生物

Country Status (8)

Country Link
US (2) US8324243B2 (https=)
EP (1) EP2139860A2 (https=)
JP (1) JP5555494B2 (https=)
CN (1) CN101641332B (https=)
AU (1) AU2008248475B2 (https=)
CA (1) CA2680803A1 (https=)
FR (1) FR2913976B1 (https=)
WO (1) WO2008135671A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913976B1 (fr) * 2007-03-23 2013-04-26 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.
EP2149567A1 (en) * 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
KR101514285B1 (ko) 2013-08-09 2015-04-22 숙명여자대학교산학협력단 아미노다이하이드로퀴놀린 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 암 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5736192A (en) * 1980-08-13 1982-02-26 Nippon Oil Co Ltd Metal inactivator and its composition
IL130324A0 (en) * 1999-06-07 2000-06-01 Yeda Res & Dev Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
CN1295218C (zh) * 2004-06-18 2007-01-17 中国科学院广州化学研究所 单官能团8－羟基喹啉金属配合物的烯类单体及其制法和用途
FR2913976B1 (fr) * 2007-03-23 2013-04-26 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AI-YU SHEN, et al..Synthesis and Cytotoxicity Evaluation of Some 8-Hydroxyquinoline Derivatives.《J.Pharm.Pharmacol.》.1999,第51卷第543-548页. *

Also Published As

Publication number Publication date
US8614230B2 (en) 2013-12-24
AU2008248475A1 (en) 2008-11-13
CN101641332A (zh) 2010-02-03
US20130102630A1 (en) 2013-04-25
EP2139860A2 (fr) 2010-01-06
CA2680803A1 (en) 2008-11-13
AU2008248475B2 (en) 2013-10-03
WO2008135671A3 (fr) 2009-05-22
FR2913976B1 (fr) 2013-04-26
JP5555494B2 (ja) 2014-07-23
JP2010522147A (ja) 2010-07-01
FR2913976A1 (fr) 2008-09-26
US8324243B2 (en) 2012-12-04
WO2008135671A2 (fr) 2008-11-13
US20100120856A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
Utreja et al. Schiff bases and their metal complexes as anti-cancer agents: A review
CN101641332B (zh) 用于治疗癌症的胺化的羟基喹啉类衍生物
US11390591B2 (en) 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
Pati et al. Novel metal chelators thiosemicarbazones with activity at the σ 2 receptors and P-glycoprotein: an innovative strategy for resistant tumor treatment
JP7301856B2 (ja) インドールアミン－２，３－ジオキシゲナーゼ阻害剤およびその調製方法と使用
BRPI0619551A2 (pt) derivados de jasmonato aprimorados, composições farmacêuticas e métodos de uso dos mesmos
CN103214422B (zh) 一类新型取代胺基咪唑酮衍生物的制备方法及抗癌作用
JP6695875B2 (ja) 抗がん剤としての新規な１，３，５−トリアジン系ｐｉ３ｋ阻害剤及びその製造方法
JP2009534449A (ja) １，４−ナフトキノン系化合物、該化合物を含んでなる組成物、およびこれらの化合物の抗がん剤としての使用
CN104098457B (zh) 四氢姜黄素类似物及其制备和应用
CN107739381B (zh) 莪术醇衍生物及其在制备抗肿瘤药物中的应用
CN103435554A (zh) 2-苯氨基苯并咪唑类化合物及其用途
ES2924575A1 (es) Derivados de quinolilnitronas para su uso en la prevencion y el tratamiento de la isquemia cerebral, ictus isquemico y enfermedades neurodegenerativas
WO2018201939A1 (zh) 苯并吲唑类衍生物的前药及其制备方法、应用
CN106800563B (zh) 一种左氧氟沙星醛缩氨基硫脲类衍生物及其制备方法和应用
HK40001487B (en) 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
CN106674104A (zh) 氟罗沙星醛缩4‑芳基氨基硫脲类衍生物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140312

Termination date: 20160325

CF01 Termination of patent right due to non-payment of annual fee